• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利妥昔单抗治疗伴有脱髓鞘疾病的强直性脊柱炎患者：病例报告及文献复习。

Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.

机构信息

Department of Medicine, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada.

出版信息

Clin Rheumatol. 2012 Aug;31(8):1259-61. doi: 10.1007/s10067-012-2002-8. Epub 2012 May 27.

DOI:10.1007/s10067-012-2002-8
PMID:22644089
Abstract

Tumor necrosis factor inhibitors (TNFI) are novel therapies used to treat ankylosing spondylitis (AS). Demyelinating disease is a rare but serious complication of TNFI. We report a patient with a case of AS who developed demyelinating disease secondary to TNFI and was treated successfully with rituximab.

摘要

肿瘤坏死因子抑制剂（TNFI）是一种新型治疗方法，用于治疗强直性脊柱炎（AS）。脱髓鞘疾病是 TNFI 的一种罕见但严重的并发症。我们报告了 1 例 AS 患者，因 TNFI 继发脱髓鞘疾病，经利妥昔单抗治疗后成功。

相似文献

1
Rituximab in a patient with ankylosing spondylitis with demyelinating disease: a case report and review of the literature.利妥昔单抗治疗伴有脱髓鞘疾病的强直性脊柱炎患者：病例报告及文献复习。
Clin Rheumatol. 2012 Aug;31(8):1259-61. doi: 10.1007/s10067-012-2002-8. Epub 2012 May 27.
2
Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.强直性脊柱炎肿瘤坏死因子-α阻断治疗应答和停药的基线预测因素：一项前瞻性纵向观察队列研究。
Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.
3
Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.阿达木单抗、依那西普和英夫利昔单抗治疗强直性脊柱炎：系统评价与经济学评估
Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. doi: 10.3310/hta11280.
4
A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis.一项为期 2 年的依那西普和英夫利昔单抗治疗强直性脊柱炎的疗效和安全性的开放性随机对照研究。
Rheumatol Int. 2010 Sep;30(11):1437-40. doi: 10.1007/s00296-009-1157-3. Epub 2009 Oct 23.
5
Efficacy of antitumor necrosis factor(α) agents on patients with ankylosing spondylitis.抗肿瘤坏死因子（α）药物治疗强直性脊柱炎的疗效。
Am J Med Sci. 2013 Dec;346(6):455-61. doi: 10.1097/MAJ.0b013e3182926a23.
6
Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.肿瘤坏死因子-α抑制剂在强直性脊柱炎中的剂量调整在临床实践中有效维持缓解。
J Rheumatol. 2012 Jul;39(7):1418-23. doi: 10.3899/jrheum.111337. Epub 2012 Jun 15.
7
[Biologicals in the treatment of rheumatic diseases].[生物制剂在风湿性疾病治疗中的应用]
Dtsch Med Wochenschr. 2006 Oct 13;131(41):2279-85. doi: 10.1055/s-2006-951364.
8
Investigation of effects of two-different treatment modalities on nerve conduction in patients with ankylosing spondylitis.探讨两种不同治疗方式对强直性脊柱炎患者神经传导的影响。
Rheumatol Int. 2012 Feb;32(2):431-4. doi: 10.1007/s00296-010-1677-x. Epub 2010 Dec 1.
9
Patient-tailored dose reduction of TNF-α blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice.在日常临床实践中，针对疾病活动度稳定且较低的强直性脊柱炎患者，进行个体化的肿瘤坏死因子-α阻断剂剂量减少。
Clin Exp Rheumatol. 2015 Mar-Apr;33(2):174-80. Epub 2015 Mar 10.
10
Risk of herpes zoster in patients receiving anti-TNF-α in the prospective French RATIO registry.在法国前瞻性RATIO注册研究中接受抗TNF-α治疗患者的带状疱疹风险
J Invest Dermatol. 2012 Mar;132(3 Pt 1):726-9. doi: 10.1038/jid.2011.383. Epub 2011 Nov 24.

引用本文的文献

1
Sixteen syndrome: a rare presentation of central demyelination.十六号综合征：一种罕见的中枢脱髓鞘病变表现。
BMJ Case Rep. 2023 Jan 10;16(1):e250440. doi: 10.1136/bcr-2022-250440.
2
Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.未确诊的强直性脊柱炎病例中的血清阳性视神经脊髓炎：一个神经风湿病学难题
Qatar Med J. 2022 Jul 7;2022(3):29. doi: 10.5339/qmj.2022.29. eCollection 2022.
3
B Cell Involvement in the Pathogenesis of Ankylosing Spondylitis.B 细胞在强直性脊柱炎发病机制中的作用。

本文引用的文献

1
Marked reduction of sacroiliac joint inflammation on magnetic resonance imaging in a patient with ankylosing spondylitis after rituximab treatment.利妥昔单抗治疗后，一名强直性脊柱炎患者骶髂关节炎症在磁共振成像上显著减轻。
J Rheumatol. 2011 Sep;38(9):2083-4. doi: 10.3899/jrheum.110132.
2
Rituximab for secondary progressive multiple sclerosis: a case series.利妥昔单抗治疗继发进展型多发性硬化症：病例系列。
CNS Drugs. 2011 Jul;25(7):607-13. doi: 10.2165/11589390-000000000-00000.
3
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis.
Int J Mol Sci. 2021 Dec 11;22(24):13325. doi: 10.3390/ijms222413325.
4
Systematic review of the role of rituximab in treatment of antineutrophil cytoplasmic autoantibody-associated vasculitis, hepatitis C virus-related cryoglobulinemic vasculitis, Henoch-Schönlein purpura, ankylosing spondylitis, and Raynaud's phenomenon.利妥昔单抗在治疗抗中性粒细胞胞浆抗体相关性血管炎、丙型肝炎病毒相关冷球蛋白血症性血管炎、过敏性紫癜、强直性脊柱炎和雷诺现象中作用的系统评价
Open Access Rheumatol. 2017 Dec 15;9:201-214. doi: 10.2147/OARRR.S149373. eCollection 2017.
2010 年更新的 ASAS/EULAR 强直性脊柱炎治疗建议。
Ann Rheum Dis. 2011 Jun;70(6):896-904. doi: 10.1136/ard.2011.151027.
4
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.利妥昔单抗附加治疗突破性复发多发性硬化症：一项为期 52 周的 II 期试验。
Neurology. 2010 Jun 8;74(23):1860-7. doi: 10.1212/WNL.0b013e3181e24373.
5
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.肿瘤坏死因子阻滞剂初治的活动性强直性脊柱炎患者与肿瘤坏死因子阻滞剂治疗失败患者对利妥昔单抗的不同反应：一项为期24周的临床试验。
Arthritis Rheum. 2010 May;62(5):1290-7. doi: 10.1002/art.27383.
6
Rituximab in the spondyloarthropathies: data of eight patients followed up in the French Autoimmunity and Rituximab (AIR) registry.利妥昔单抗治疗脊柱关节炎：法国自身免疫与利妥昔单抗（AIR）注册研究中8例患者的随访数据。
Ann Rheum Dis. 2010 Feb;69(2):471-2. doi: 10.1136/ard.2008.107102.
7
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.利妥昔单抗治疗原发性进行性多发性硬化症患者：一项随机双盲安慰剂对照多中心试验的结果
Ann Neurol. 2009 Oct;66(4):460-71. doi: 10.1002/ana.21867.
8
The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B.使用利妥昔单抗治疗一名强直性脊柱炎合并乙型肝炎患者。
Rheumatology (Oxford). 2008 Nov;47(11):1732-3. doi: 10.1093/rheumatology/ken362. Epub 2008 Sep 11.
9
Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis.
Joint Bone Spine. 2008 Jul;75(4):510-1. doi: 10.1016/j.jbspin.2008.01.023. Epub 2008 May 23.
10
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.利妥昔单抗治疗复发缓解型多发性硬化症：一项为期72周的开放标签I期试验。
Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363.